Join your peers and 13 leading experts at New Horizons in Obesity Management 2026 — your final chance to attend this free, global, CME-accredited* virtual event 🔗 ow.ly/YntN50ZbRxv Explore key topics including: ✨ Preventing irreversible organ damage ✨ How obesity drives cardiovascular disease ✨ Modern obesity pharmacotherapy ✨ The CKM-Obesity Disease Model Be part of a transformative learning experience designed to support evidence-based obesity care.

Obesity is not a single-specialty challenge. That is why, during Session 2 of New Horizons in Obesity Management, attendees will be able to choose from three parallel specialty tracks, each designed to support the way obesity is managed in practice. ➡️ Interception – Early CKM risk ➡️ Modification – Established CKM risk ➡️ Escalation – Progressive organ disease 🗓️ Wednesday 17 June – 14:15 - 15:45 CEST | 08:15 - 09:45 ET Register Here: ow.ly/bzR750Z9pN0 The symposium 'Real-World Decisions: Implementing Disease-Modifying Obesity Therapy in Primary Care' is supported by an unrestricted educational grant from Boehringer Ingelheim.

Join us on Wednesday 17 June 2026 for a practical 45-minute symposium on obesity care in primary care. Chaired by Richard Hobbs, the expert panel will discuss: 🔹 Obesity as a chronic disease within CKM care 🔹 Current evidence for pharmacologic obesity therapies 🔹 Practical approaches to starting, referring and monitoring treatment 🔹 Patient communication strategies and MDT integration Register now to gain practical insights for implementing disease-modifying obesity therapy in primary care: ow.ly/vRo750Z7eI0 This symposium is supported by an unrestricted educational grant from Boehringer Ingelheim.

💫 If obesity and #CKM overlap in your daily practice then New Horizons in Obesity Management is made for you 👉 ow.ly/cwMh50YTaNt 🗓️ Returning on Wednesday 17 June 2026, this one-day event brings together global leaders to explore shared disease pathways and personalised treatment strategies.

📚 Latest News : "Tirzepatide Linked to Lower Cardiorenal Events vs Dulaglutide" 🔓Access it here 👉 ow.ly/XZ4w106xMXt

📚 Latest News : "SOUL: Oral Semaglutide Improves CV Risk Factors in T2D" 🔓Access it here 👉 ow.ly/O01l106xAAa

✨The full e-SPACE CRM 2026 programme is now available on demand! Gain insights from global leaders in cardiology, nephrology, diabetology and obesity management. Watch expert-led #CRM sessions for free! 🔗 Access Here 👉 espace-crm.org/2026/v/s-3987… #CardioRenalMetabolic #CKM #Cardiology

📚 Latest News : "Ez-PAVE: Lower LDL-C Target Reduces CV Events" 🔓Access it here 👉 ow.ly/AfAw106xkYC

📚 Latest News : "hsCRP Improves CV Risk Prediction in Primary Prevention" 🔓Access it here 👉 ow.ly/XCAy106xi0J

🔴 Day Two Is Live Now! Join your peers and 60 leading experts at e-SPACE CRM 2026 – your final chance to be part of this free, global and CME-accredited virtual event. 🔗 Join live: ow.ly/38rX50YGX5O #CardioRenalMetabolic #CKM #HeartFailure #KidneyHealth

🚨 Day Two Is About To Begin e-SPACE Cardio-Renal-Metabolic 2026 continues shortly. There’s still time to join. Today’s programme explores obesity as a central driver in CRM, key biomarkers, and combination therapy strategies shaping clinical practice. 🔗 Register now: ow.ly/gH6650YGWfi #CardioRenalMetabolic #CKM #Cardiology

✅ And that's a wrap for Day One of e-SPACE CRM 2026! We want to say a huge thank you to the Course Directors Christoph Wanner and Shalley Zieroth, the faculty whose expertise made this programme possible, and Translational Medicine Academy for their valued collaboration. 🔗 We hope you can join us tomorrow at 10:00 BST: ow.ly/lrsX50YGVNX #CardioRenalMetabolic #CKM #Cardiology

🔴 Day One of e-SPACE Is Live! ow.ly/zRHk50YGGfA Join now to access today’s key sessions: • Optimising outcomes in CKM disease • Evolving guidelines across cardiology, nephrology and diabetes • SGLT2 inhibitors, MRAs and GLP1 RAs in practice • HFpEF insights and emerging therapies #CardioRenalMetabolic #CKM #HeartFailure #DiabetesCare #KidneyHealth

🚨 We’re About To Begin e-SPACE Cardio-Renal-Metabolic 2026 goes live shortly. There’s still time to join. 🔗 Register now: espace-crm.org/2026?utm_sour… Explore the intersection of cardiovascular disease, diabetes and chronic kidney disease through expert-led sessions, live panels and practical discussion. Join a global faculty tackling real-world CKM challenges. #CardioRenalMetabolic #CKM #Cardiology

Are you ready for e-SPACE CRM 2026? 💫 The sixth edition of e-SPACE CRM is just days away. Taking place this Friday, now is the time to secure your place and join a global community of clinicians focused on improving CRM care 🔗 ow.ly/g5Pk50YF2Xi #eSPACECRM26 #CRM #CVRM

✨ Obesity isn’t just a risk factor; it’s a driver of cardio-kidney-metabolic disease. Join global leaders on 17 June 2026 for New Horizons in Obesity Management to explore how modern therapies can modify disease progression, not just weight, and how to apply this in real-world practice 🔗 ow.ly/YzWi50YCnHQ #NHOM2026 #CKM

💫 New from ACC 2026 ➡️ updated recommendations on the evolving role of EPA, fibrates and N-3 fatty acids for cardiovascular prevention strategies: radcliffecvrm.com/video-inde… Explore how these updates apply to high- and very high-risk patients and how they align with existing guidance. This programme is supported by an unrestricted educational grant from Amarin.

We have more evidence in cardio-renal-metabolic medicine than ever before. Yet patients are still falling through the gaps between specialties. Data alone doesn’t change practice. e-Space CRM is where adoption actually happens! ✅ Free & virtual, live on 10–11 April 2026. Register here: ow.ly/NBvu50YBeqO #eSPACECRM26 #CRM #CVRM

📚 Latest News : "SOUL: Oral Semaglutide Aids CV Risk in T2D" 🔓Access it here 👉 ow.ly/pvTV106wt46

📚 Latest News : "GLP-1RAs Cut Cardiorenal Events in Type 1 Diabetes" 📚 New study: GLP-1RAs show cardiorenal benefits in type 1 diabetes, reducing the risk of MACEs, ESKD, and heart failure hospitalisation without increasing safety concerns. 👉 ow.ly/vy19106wr4x